Skip to main content

New Stock Recommendation: JM Smucker & Co.

Spread the profits in the Fall with the sweet tasting stock of J. M. Smucker Co. Here is a flyer that you may want to consider. This $7.1 billion dollar company is a giant in it's space. No one does it like Smucker's (SJM), yes the peanut butter and jelly and more company.The stock has a very low price to earnings ratio of 14.48, which suggest that there is lots of room for price appreciation, if management makes the right moves in the coming months. In addition, the stock has a low volatility beta ranking of (.7), and pays a good dividend of 2.68%. Not bad when 1 year Cd's are yielding less than 1.37%. Although the stock is trading toward the high range of $59 to $60 dollars, it still represents a possible growth or acquisition play for the patient investor. Pick up at these prices and spread the profits in the Fall, like 'spreading peanut butter and jelly on toast', by adding this stock to your portfolio. Contact Best Advisor Rick @1-877-788-1732 for detailed research reports and advice on this stock at IAPeQ.com.
Labels:

Comments

Post a Comment

Popular posts from this blog

Morning Update

By Rick Walter Still working on putting together a strong biotech portfolio. Here is a good general article on the state of the biotech industry that was posted yesterday on the online Wall Street Journal's site- Biotech Stocks Hot Right Now, Ho-Hum in the Long Run.
Post a Comment
Read more

Portfolio Update

By Rick Walter I have posted a new Biotechnology portfolio . It's total return as of November 25, 2009 is 3.4%. However, to download and use it you will have to subscribe to the portfolio, of course. On an important note, I consider each portfolio to be well diversified in its particular sector but I've recently decided to add stock futures and options positions to each portfolio which will increase each portfolio's return but lower the risks going forward.
Post a Comment
Read more

Biotech Pump and Dump

By Rick Walter Building a good Biotechnology portfolio has turned out to be a bit of a task. I have one on the table, but feel that it's a little too aggressive and risky, especially for today's market. Funding for most Biotech ventures- old or new, have either dried up or have been put on hold. This portfolio that I am building is too much of a pure Biotech play. It would be feast or famine on the returns. Let me explain. I remember when I was a young broker, I worked for this small outfit in Florida where the office manager and a few other brokers, including myself, would get all pumped up over a stock called Celi. I believe that the stock is now trading on the Amex as (Cel-Sci: CVM ). Well the stock was always on the verge of getting approval for some phase of cancer treatment therapy. Whenever the company released news, we would run the stock up as high as the market makers would let us run it- ($1.30 to $2.30 per share) before we banged it back down to previous lows of .30...
Post a Comment
Read more